Kenneth dEntremont - Medexus Pharmaceuticals CEO Director
| MDP Stock | 2.86 0.12 4.38% |
Insider
Kenneth dEntremont is CEO Director of Medexus Pharmaceuticals
| Address | 10 King Street East, Toronto, ON, Canada, M5C 1C3 |
| Phone | 877 422 5242 |
| Web | https://www.medexus.com |
Medexus Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0162 % which means that it generated a profit of $0.0162 on every $100 spent on assets. This is way below average. Medexus Pharmaceuticals' management efficiency ratios could be used to measure how well Medexus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 15th of February 2026, Return On Tangible Assets is likely to grow to 0.02. Also, Return On Capital Employed is likely to grow to 0.10. At this time, Medexus Pharmaceuticals' Return On Tangible Assets are very stable compared to the past year. As of the 15th of February 2026, Debt To Assets is likely to grow to 0.42, while Intangible Assets are likely to drop about 43.7 M.Similar Executives
| Found 4 records | INSIDER Age | ||
| Bernard BSc | Cardiol Therapeutics Class | N/A | |
| MBA MBA | Cardiol Therapeutics Class | N/A | |
| CA CMA | Cardiol Therapeutics Class | N/A | |
| Trevor Burns | Cardiol Therapeutics Class | N/A | |
Management Performance
| Return On Equity | -0.0064 | ||||
| Return On Asset | 0.0162 |
Medexus Pharmaceuticals Leadership Team
Elected by the shareholders, the Medexus Pharmaceuticals' board of directors comprises two types of representatives: Medexus Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medexus. The board's role is to monitor Medexus Pharmaceuticals' management team and ensure that shareholders' interests are well served. Medexus Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medexus Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Brian Peters, Vice States | ||
| Brendon Bushman, Chief Officer | ||
| Richard Labelle, Chief Officer | ||
| Marcel Konrad, Chief Officer | ||
| Michael Adelman, US Mang | ||
| Ian Brown, General Secretary | ||
| Kenneth dEntremont, CEO Director | ||
| Tina CFA, Executive Relations | ||
| Bill Poncy, Senior States | ||
| Brendon Buschman, Chief Officer |
Medexus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medexus Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0064 | ||||
| Return On Asset | 0.0162 | ||||
| Profit Margin | (0) % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 106.81 M | ||||
| Shares Outstanding | 32.42 M | ||||
| Shares Owned By Insiders | 7.23 % | ||||
| Shares Owned By Institutions | 3.36 % | ||||
| Number Of Shares Shorted | 102.71 K | ||||
| Price To Book | 1.31 X |
Pair Trading with Medexus Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medexus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medexus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Medexus Stock
The ability to find closely correlated positions to Medexus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medexus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medexus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medexus Pharmaceuticals to buy it.
The correlation of Medexus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medexus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medexus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medexus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Medexus Stock
Medexus Pharmaceuticals financial ratios help investors to determine whether Medexus Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medexus with respect to the benefits of owning Medexus Pharmaceuticals security.